Publications by authors named "Jerald Sadoff"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,225,167

Total Likes

28,885

Extended Reach

4,664,473

Social Features

629
S
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
Jerald Sadoff, Glenda Gray, An Vandebosch, Vicky Cárdenas, Georgi Shukarev, Beatriz Grinsztejn, Paul A Goepfert, Carla Truyers, Hein Fennema, Bart Spiessens

June 2021

Videos about Article: user user user 1

4 10 282 15 214 2

View All Article and Social Media Activity
I
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels

May 2021

Videos about Article: user user user 1

4 1 9 338 22 201 5

View All Article and Social Media Activity
I
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.
Alex Luedtke, Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Jerald Sadoff

iScience· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial.
Nina Hertoghs, Sanne Roels, Matthias Brückner, Jerald Sadoff, Barbara L Banbury

EBioMedicine· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines.
Rian Van Rampelbergh, Sue Pavord, Luis Anaya-Velarde, Vitalija van Paassen, Karin Hardt, Jerald Sadoff

Commun Med (Lond)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines.
Hendy Kristyanto, Leen Slaets, Esmée Braams, Ilse Scheys, Roy Heesbeen, Jerald Sadoff

J Thromb Haemost· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of Age.
Javier Ruiz-Guiñazú, Mathieu Le Gars, Vicky Cárdenas, Nathalie Vaissière, Jerald Sadoff

J Pediatric Infect Dis Soc· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.
Lindsay N Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Jerald Sadoff

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk.
Sanne Roels, Matthias Bruckner, Jerald Sadoff, Vicky Cárdenas, Chan Tang

Vaccine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.
Amy C Sherman, Jessica Tuan, Valeria D Cantos, Oladunni Adeyiga, Scott Mahoney, Jerald Sadoff

Clin Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
Mathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, Dirk Heerwegh, Fisseha Tesfaye

Vaccine· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Vicky Cárdenas, Mathieu Le Gars, Carla Truyers, Javier Ruiz-Guiñazú, Frank Struyf, Jerald Sadoff

Vaccine· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.
Catherine Jacob-Dolan, Michelle Lifton, Olivia C Powers, Jessica Miller, Nicole P Hachmann, Jerald Sadoff

iScience· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Craig A Magaret, Li Li, Allan C deCamp, Morgane Rolland, Michal Juraska, Jerald Sadoff

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Christy A Comeaux, Stephan Bart, Arangassery Rosemary Bastian, Vladislav Klyashtornyy, Els De Paepe, Jerald Sadoff

J Infect Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute quantitation of binding antibodies from clinical samples.
Chan Tang, Annemiek Verwilligen, Jerald Sadoff, Boerries Brandenburg, Eveline Sneekes-Vriese

NPJ Vaccines· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Yannic C Bartsch, Deniz Cizmeci, Dansu Yuan, Nickita Mehta, Jeroen Tolboom, Jerald Sadoff

J Virol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff

CPT Pharmacometrics Syst Pharmacol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Frank Struyf, Karin Hardt, Rian Van Rampelbergh, Georgi Shukarev, Ajinkya Inamdar, Jerald Sadoff

Vaccine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
Christine B Turley, LaKesha Tables, Trevon Fuller, Lisa J Sanders, Hyman Scott, Jerald Sadoff

Vaccine· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Deborah A Theodore, Angela R Branche, Lily Zhang, Daniel S Graciaa, Madhu Choudhary, Jerald Sadoff

JAMA Netw Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.
Eric K H Chan, Valerie Williams, Carla Romano, Sheri Fehnel, Ashley F Slagle, Jerald Sadoff

J Patient Rep Outcomes· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
Craig Magaret, Li Li, Allan deCamp, Morgane Rolland, Michal Juraska, Jerald Sadoff

Res Sq· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Anna Dari, Muriel Boulton, Martine Neyens, Mathieu Le Gars, Belén Valenzuela, Jerald Sadoff

Clin Pharmacol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, Stephan Bart, John Ervin, Jerald Sadoff

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers

Lancet Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
Youyi Fong, Adrian B McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, Jerald Sadoff

Nat Microbiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis